Prostate cancer survivors aged 65-74 were more likely than those aged under 55 to be PSA-detected (Adjusted odds ratio (AOR): 0.83, 95% confidence interval (CI): 0.72-0.95), while compared to men diagnosed at stage I/II, men diagnosed at stage III (AOR: 1.20, 95% CI: 1.12-1.28) or stage IV (AOR: 2.03, 95% CI: 1.82-2.27) were more likely to have been symptomatic. Here, KLK3 is linked to prostate carcinoma.